晚期早产风险患者产前皮质类固醇应用:随机对照试验的系统评价与Meta分析
该系统评价纳入6项随机对照试验共5143例分娩,评估34 0/7至36 6/7周产前皮质类固醇的效果。结果显示呼吸窘迫综合征发生率两组相似(RR 0.89,95%CI 0.68-1.16),但皮质类固醇组持续气道正压通气≥2小时(RR 0.78,95%CI 0.65-0.94;P=.007)和表面活性物质使用(RR 0.61,95%CI 0.38-0.99;P=.04)显著降低。
要点
- 晚期早产(34 0/7-36 6/7周)产前皮质类固醇未降低呼吸窘迫综合征发生率。
- 产前皮质类固醇显著减少持续气道正压通气≥2小时使用(RR 0.78)。
- 产前皮质类固醇显著减少表面活性物质使用(RR 0.61)。
核心结论
- 在34 0/7-36 6/7周有早产风险的患者中,产前皮质类固醇不降低呼吸窘迫综合征,但减少持续气道正压通气超过2小时和表面活性物质的使用。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase.com、Scopus、Cochrane CENTRAL、CINAHL Ultimate、ClinicalTrials.gov和WHO ICTRP等数据库及灰色文献,从建库至2024年7月15日。
- 纳入比较产前皮质类固醇与安慰剂或无治疗的随机对照试验,对象为34 0/7-36 6/7周单胎妊娠。
- 共纳入6项随机对照试验,涵盖5143例分娩;采用Cochrane RoB 2工具评估偏倚风险,使用DerSimonian and Laird随机效应模型。
主要发现
- 呼吸窘迫综合征发生率两组相似(RR 0.89,95%CI 0.68-1.16;6项试验,5163名新生儿)。
- 新生儿暂时性呼吸增快发生率两组相似(RR 0.93,95%CI 0.67-1.29;4项试验,4292名新生儿)。
- 产前皮质类固醇组持续气道正压通气≥2小时使用率显著低于对照组(RR 0.78,95%CI 0.65-0.94;P=.007;4项试验,4760名新生儿)。
- 产前皮质类固醇组表面活性物质使用率显著低于对照组(RR 0.61,95%CI 0.38-0.99;P=.04;2项试验,3100名新生儿)。
- 机械通气(RR 0.75,95%CI 0.51-1.11;5项试验,5069名新生儿)、NICU入住率(RR 0.92,95%CI 0.82-1.03;6项试验,5169名新生儿)、低血糖(RR 1.28,95%CI 0.93-1.74;4项试验,4750名新生儿)、新生儿死亡(RR 0.94,95%CI 0.34-2.63;5项试验,4920名新生儿)和5分钟Apgar评分(MD 0.07,95%CI -0.03至0.17;2项试验)两组无显著差异。
关键数值与推荐
- 主要结局呼吸窘迫综合征:RR 0.89,95%CI 0.68-1.16(6项试验,5163名新生儿)。
- 持续气道正压通气≥2小时:RR 0.78,95%CI 0.65-0.94;P=.007(4项试验,4760名新生儿)。
- 表面活性物质使用:RR 0.61,95%CI 0.38-0.99;P=.04(2项试验,3100名新生儿)。
- 低血糖:RR 1.28,95%CI 0.93-1.74(4项试验,4750名新生儿)。
- NICU入住率:RR 0.92,95%CI 0.82-1.03(6项试验,5169名新生儿)。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effectiveness of antenatal corticosteroid administration in the late preterm period (34 0/7-36 6/7 weeks of gestation). DATA SOURCES: A Medical Librarian performed a search in the following databases and grey literature sources from inception until July 15, 2024: PubMed (NLM), Embase.com (Elsevier), Scopus (Elsevier), Cochrane CENTRAL (Wiley), CINAHL Ultimate (EBSCOHost), ClinicalTrials.gov and WHO ICTRP. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: This study screened studies using 2 independent reviewers based on the predefined inclusion/exclusions criteria. This study included randomized controlled trials (RCTs) comparing antenatal corticosteroid administration with placebo or with no treatment given to individuals with singleton gestations at 34 0/7-36 6/7 weeks. STUDY APPRAISAL AND SYNTHESIS METHODS: This study appraised the included randomized controlled trials using 2 independent reviewers based on the Cochrane RoB 2 tool and other assessment measures. The primary outcome was the incidence of respiratory distress syndrome (RDS) (6 trials, 5163 newborns). Secondary outcomes included hypoglycemia (as defined by each trial) (4 trials, 4750 newborns), incidence of transient tachypnea of the newborn (TTN) (4 trials, 4292 newborns), neonatal intensive care unit (NICU) admission (6 trials, 5169 newborns), continuous positive airway pressure (CPAP) use for ≥2 hours (4 trials, 4760 newborns), surfactant administration (2 trials, 3100 newborns), neonatal sepsis (4 trials, 4754 newborns), neonatal mortality (5 trials, 4920 newborns), need for resuscitation in the labor suite (4 trials, 4647 newborns), hyperbilirubinemia (2 trials, 1156 newborns), necrotizing enterocolitis (NEC) (2 trials, 3710 newborns), mechanical ventilation (5 trials, 5069 newborns) and Apgar Score at 5 minutes of life (2 trials) and maternal outcomes. The summary measures were reported as relative risk (RR) or as mean difference (MD) with 95% of confidence interval (CI) using the random effects model of DerSimonian and Laird. I-squared(Higgins I2) greater than 0% was used to identify heterogeneity. RESULTS: Six RCTs, encompassing 5143 deliveries, were included for analysis. The incidence of RDS was similar in the 2 groups (RR 0.89, 95% CI 0.68-1.16), as was the rate of transient tachypnea of the newborn (TTN) (RR 0.93, 95% CI 0.67-1.29). Antenatal corticosteroids significantly reduced the use of CPAP ≥2 hours (RR 0.78, 95% CI 0.65-0.94; P=.007) and surfactant (RR 0.61, 95% CI 0.38-0.99; P=.04) compared to the control. There were no significant differences in mechanical ventilation (RR 0.75, 95% CI 0.51-1.11), NICU admission rate (RR 0.92, 95% CI 0.82-1.03), hypoglycemia (RR 1.28 95% CI 0.93-1.74) neonatal death (RR 0.94, 95% CI 0.34-2.63), Apgar Score at 5 min (MD 0.07 95% CI 95% -0.03, 0.17) between the 2 groups. The need for resuscitation, incidence of neonatal sepsis, hyperbilirubinemia, neonatal enterocolitis, cesarean delivery, chorioamnionitis, fever and postpartum endometritis were also similar between the 2 groups. CONCLUSIONS: Antenatal corticosteroids administered between 34 0/7-36 6/7 weeks of gestation in patients at risk of preterm birth do not reduce RDS but reduce the use of CPAP for more than 2 hours and surfactant. SYSTEMATIC REVIEW REGISTRATION: CRD42024548167. El resumen está disponible en Español al final del artículo.
引用
- Zullo F, Gulersen M, Di Mascio D, et al. Antenatal corticosteroids for patients at risk of late preterm birth: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol MFM. 2025. PMID: 40418984. doi:10.1016/j.ajogmf.2025.101709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。